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ABSTRACT
Sarcoidosis is a systemic inflammatory disease that can affect almost any organ, 
but the respiratory system is affected in more than 90% of the cases. To elicit an 
immune response, an antigen(s) is processed by antigen-presenting cells (APCs), 
e.g. alveolar macrophages (AMs), and is presented in association with HLA-
molecules to specific T cells, using their T cell receptor (TCR). In sarcoidosis, this 
interaction between the innate and adaptive immune system leads to an exaggerated 
immune response and formation of non-caseating granulomas in affected organs. 
The causative antigen remains elusive. To generate the sarcoid inflammatory 
process, the genetic background as well as exposure for antigens, endogenous or 
exogenous, is it of importance. Clinically, sarcoidosis patients can be divided into 
two major groups, i.e. patients with Löfgren’s syndrome (LS) or with non-Löfgren’s 
syndrome (non-LS). LS is a clinically distinct and well-defined phenotype that is 
characterized by an acute onset and is associated with specific HLA molecules, 
i.e. HLA-DRB1*03. In most of the LS patients, the disease resolves within two 
years. On the other hand, non-LS patients constitute a heterogeneous group and 
are prone to develop a chronic disease course.
Collecting cells from the deep lung compartment via bronchoalveolar lavage (BAL) 
enabled many researchers to explore immunological mechanisms in the alveolar 
space. In a healthy individual, BAL fluid (BALF) are mainly macrophages, some 
lymphocytes, and fewer neutrophils, and eosinophils; basophils and mast cells are 
rare. BALF from sarcoidosis patients contains an increased number of all these 
cell types, especially lymphocytes.
The first two studies (I, II) aimed to shed some light on the expression of cell regu-
latory markers in LS and non-LS patients. Macrophages are classically subdivided 
into two major subtypes, i.e. M1 – known as proinflammatory macrophages – and 
M2 – known as remodeling macrophages. We found in the first study (I) reduced 
gene expression of toll-like receptor 2 (TLR2: M1 associated marker) – mainly 
in LS patients – and increased expression of CCL18 (M2 associated marker) in 
AM of sarcoidosis patients. This finding could indicate a shift toward M2-like 
macrophages in sarcoidosis. The reduced TLR2 expression in LS patients might 
allow for a more effective immune response leading to resolution of granulomas. 
The CCL18 chemokine is known to act as T cell chemoattractant and can also 
induce collagen production in fibroblasts. Hence, the increased expression of 
CCL18 in AM of patients might attract T cells to the lung in the early stages of 
the disease and exhibit a profibrotic role in more advanced disease. The second 
study (II) explored the expression of specific transcription factors/nuclear recep-
tors known to have regulatory roles in inflammatory diseases, i.e. the peroxisome 
proliferator-activated receptors (PPARs): PPARα, PPARβ/δ and PPARγ. Compared 
to LS patients, PPARα expression was downregulated in BALF and blood CD4+ 
and CD8+ T cells in non-LS patients. Thus, CCL18 and PPARα could be used as 
biomarkers and might help in identifying patients at increased risk of developing 
more advanced lung disease.
The third study (III) aimed to explore the influence of patient phenotypes on BALF 
cell differential counts. We found that genetic variants associated with risk of LS 
and clustered in the extended MHC region were associated with the quantitative 
levels of BALF macrophages, lymphocytes, and neutrophils. Genetic variants 
associated with non-LS and located in the MHC II region associated with the 
quantitative levels of BALF macrophages only. In addition, these genetic  variants 
exhibit regulatory effects on other genes in the lung, blood, T cells, B cells, macro-
phages and neutrophils.
The fourth study (IV) aimed to utilize data from a BALF registry of pulmonary 
sarcoidosis patients (LS and non-LS) to identify BALF cells that could predict 
disease severity (defined as advanced chest radiographs, reduced pulmonary 
function, or necessity for treatment) and/or chronicity (non-resolving course after 
two years). Compared with LS-resolving patients, LS-chronic patients exhibited 
higher BALF lymphocytes, neutrophils, and eosinophils. Additionally, in newly 
diagnosed LS patients, increased BALF neutrophils and basophils were more likely 
to associate with more severe disease; and increased BALF lymphocytes count 
was more likely to associate with a chronic disease course. In non-LS patients, 
increased BALF mast cells associated with a more severe and a chronic (non-
resolving) disease, and increased BALF lymphocytes, neutrophils, eosinophils, 
and basophils associated with a more severe disease.
In summary, searching for biomarkers, we identified two possible markers for 
severe and/or chronic disease, i.e. PPARα and CCL18. In study III and IV, we 
showed that genetic variants associated with LS and non-LS can influence BALF 
cell counts and that increased BALF neutrophils, eosinophils, lymphocytes, 
basophils and notably mast cells have prognostic implication in newly diagnosed 
sarcoidosis patients.
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11 THE LUNG
The primary function of lung parenchyma is gas exchange. The lungs are continuously 
exposed to multiple environmental agents and diverse microorganisms. Therefore, 
the lungs have a critical role in immunity. The respiratory system consists of air-
ways and lung tissue. The left lung contains two lobes: an upper and lower lobe. 
The right lung contains three lobes: an upper, middle and lower lobe. Each lung 
has ten bronchopulmonary segments. The airways consist of the trachea (windpipe) 
which divides into two main bronchi, i.e. the left and the right bronchus. The two 
main bronchi continue to branch into lobar, segmental, and smaller airways which 
continue to divide until they reach 1mm in diameter. Bronchioles have no cartilage 
and include the terminal and respiratory bronchioles (0,5 mm diameter) which are 
last airways before the small airway sac starts (alveolus). The lungs contain approxi-
mately 300 million alveoli with a surface area of about 70 m2.
Figure 1. Gross anatomy of the lung simplified.
22 THE IMMUNE SYSTEM
Historically, innate and adaptive immune responses have been treated as separate, 
and the latter being considered more advanced. It is now clear this is not the case. 
Innate immune responses provide the essential early controls and deconditioning 
needed for an efficient adaptive immune response. Innate responses occur within 
minutes or hours of infection, whereas initiation of an effective adaptive immune 
response may take days.
2.1 Innate Immunity
The innate immune system is an evolutionary ancient defense system that evolved 
to protect the host against microbial pathogens. The innate immune system relies 
upon recognition of conserved molecular features of microbial pathogens or 
 damaged cells [1]. The innate immune responses are characterized by the  rapidity 
of action. Most cells of the system are derived from myeloid precursors from the 
bone marrow. These include monocytes and their derivatives-macrophages and 
dendritic cells-, granulocytes (neutrophils, basophils, and eosinophils), and mast 
cells. Natural killer (NK) and natural killer T (NKT) cells are derived from pre-
cursor cells of the lymphoid lineage. Innate immune dysfunction contributes to 
common conditions of multifactorial etiology such as sarcoidosis [2, 3].
Pattern recognition receptors (PRRs)
PRRs play a crucial role in the innate immune response by recognizing danger 
 signals that arrive either from microorganisms [pathogen-associated molecular 
 patterns (PAMPs)] or damaged cells [damage-associated molecular patterns 
(DAMPs)].
PRRs can be subdivided by their function and location into three major subtypes: 
1 – membrane-bound PRRs: TLRs and C-type lectin receptors (CLRs), 2 – cyto-
plasmic (intracellular) PRRs: Nucleotide oligomerization (NOD) like receptors 
and retinoic acid-inducible gene I (RIG-I) like receptors, and 3 – secreted PRRs 
that bind directly to invading micro-organisms [e.g. peptidoglycan recognition 
proteins (PGRs) and the leucine-rich repeat receptor (LRR)].
Human have ten TLRs that recognize a broad spectrum of pathogens. TLR2 rec-
ognizes microbial components, which include lipoteichoic acid of gram-positive 
bacteria and lipoproteins of gram-negative bacteria. TLR4 signals the presence of 
bacterial lipopolysaccharide (LPS) of gram-negative bacteria. Another Toll-like 
receptor, TLR9 recognizes bacterial and viral unmethylated CpG DNA within 
endosomes [4].
3Upon detection of a pathogen, the intracellular domain of these receptors initiates 
the activation of the transcription factor NFκB that stimulates the production of 
co-stimulatory (CD80 and CD86) molecules, cytokines (e.g., IL-1, IL-6, IL-12, 
and TNF-α), and chemokines (e.g. CXCL8) involved in anti-microbial defense 
and inflammation. Expression of the co-stimulatory molecules is necessary for 
the activation of naive CD4+ T cells and thus initiating the activation of the adap-
tive immunity [1, 5, 6].
Macrophages
In 1892, Ilya Mechnikov (1845–1916) discovered specific white blood cells that 
were able to engulf and digest bacteria by a process that he named phagocytosis. 
He called the cells according to their size: macrophages and microphages (neu-
trophils) [7]. Nicolas Tchistovitch (1860–1926) was the first to describe alveolar 
macrophages (AMs) that are capable of phagocytosis [8]. Circulating blood mono-
cytes were thought to be the sole origins of tissue macrophages. Now we know that 
most of the alveolar macrophages originate, during embryonic life, from progenitor 
cells (from the yolk sac and fetal liver) that migrate to the lung and mature locally 
before or shortly after birth [9, 10]. These alveolar macrophages are long-living 
cells and have the capability of self-renewal [11]. Several types of macrophages 
reside in the lung: bronchial macrophages, interstitial macrophages,  intravascular 
macrophages (located on the inner side of capillaries), and AMs. Interstitial macro-
phages are found in the interstitium where they interact with dendritic cells and 
interstitial lymphocytes [10, 12]. Under normal homeostasis, AMs activation is 
tightly controlled through several cell-cell interactions and soluble mediators to 
limit uncontrolled inflammatory responses [13]. Under specific conditions such 
as infection, inflammatory diseases, pollution and smoking, blood monocytes 
are recruited into lung tissue and differentiate into monocyte-derived AMs [11].
Macrophages are critical sensors for the immune system, and therefore they are 
equipped with many receptors. Macrophages can sense danger signals through 
receptors that are called pattern recognition receptors (PRRs) [5]. 
AMs can activate antigen-experienced T cells to a similar extent as dendritic cells 
(DCs), but not naïve T cells [14]. Macrophages also have opsonic receptors that 
favor phagocytosis such as the complement receptors or immunoglobulin recep-
tors. Macrophages are equipped with receptors for various chemokines, inflam-
matory cytokines (e.g. IL-1, TNF-α, IFN-γ, IL-17) and for the anti-inflammatory 
cytokines (e.g. IL-10 and TGF-β). Macrophages have adhesion receptors (e.g. 
ICAM1, VCAM1, or the β-integrins). Macrophages can be modulated by negative 
signals (e.g. acetylcholine, lipoxin) [15, 16].
4Macrophages can undergo specific differentiation into M1 (classically activated) or 
M2 (alternatively activated) phenotype in response to DAMPs, PAMPs, cytokines, 
and other mediators released in the local tissue microenvironment [17, 18]. LPS 
and IFN-γ prompt the polarization of macrophages towards the M1 phenotype. 
M1 macrophages secrete large amounts of cytokines such as IL-1β, TNF-α, IL-12, 
IL-18, and IL-23. Thus, M1-macrophages promote antigen-specific TH1 and TH17 
cell inflammatory responses. Phenotypically, M1 macrophages express high  levels 
of MHC II, and co-stimulatory molecules CD80 and CD86. M2 macrophages are 
subdivided into M2a, M2b, M2c, and M2d according to their gene expression 
profile. M2a macrophage is elicited by fungal and helminth infections, IL-4, or 
IL-13. M2b macrophage is elicited by IL-1 receptor ligands, and immune com-
plexes and LPS. TGF-β, IL-10, and glucocorticoids elicit M2c macrophage [19]. 
IL-6 and adenosine elicit M2d macrophages. In healthy individuals, AMs do not 
precisely fit into either a rigid M1 or M2 classification [13, 20].
Neutrophils
Gabriel Andral (1797–1876) and William Addison (1802–1881) were the first to 
describe leukocytes 1843 [21]. Paul Ehrlich (1854–1915) was the first to describe 
neutrophils, basophils, eosinophils and mast cells in 1879 [7, 21-23]. Besides 
their established role as a first-line defense in infectious disease, neutrophils 
play an essential role in chronic inflammation, adaptive immune responses, and 
auto immunity. Neutrophils can produce IFNγ and act as antigen-presenting cells 
(APCs) [24-28].
Basophils
Basophils are derived from hematopoietic stem cells. They have a short lifespan 
(several days) and make up <1% of the blood leukocytes [22]. It is now well 
established that basophils not only function as pro-inflammatory cells but also 
modulate the immune response in many ways. Basophils can be activated by IgE 
crosslinking to undergo rapid degranulation of granules [4]. Basophils express TLRs 
and can be activated by PAMPs [22, 29]. Activated basophils can secrete IL-4 and 
promote TH2 differentiation [30, 31]. Upon activation, basophils express MHC 
II, and co-stimulatory molecules and can activate naive CD4+ T cells by acting as 
APCs [31, 32]. Basophils can augment TH17 and TH17/TH1 effector responses [33]. 
Basophils can enhance the suppressive activity of FOXP3+ regulatory T cells [34].
Eosinophils
Eosinophils are derived from hematopoietic stem cells. Eosinophils can express 
MHC II and co-stimulatory molecules, process antigens and can activate and inter-
act with T cells to proliferate and produce cytokines in an antigen-specific manner 
[35]. Eosinophils express several families of pattern-recognition receptors (PRRs), 
5e.g. eosinophils express TLRs, although at lower levels than by neutrophils and 
macrophages [35]. Eosinophils express multiple TH1, TH2, and immunoregula-
tory cytokines, including IL-4, IL-13, IL-6, IL-10, IL-12, IFN-γ, and TNF-α, that 
are secreted rapidly and differentially in response to specific stimuli to promote 
either TH2 or TH1 cell responses [35]. Furthermore, a large quantity of IFN-γ was 
secreted in response to TH1, TH2, and inflammatory stimuli [35-37].
Mast cells
Mast cells are long-lived tissue-resident cells [38]. Mast cells derive from hemat-
opoietic stem cell but undergo terminal differentiation in tissue [39]. The lungs 
do not have numerous mast cell progenitors in a healthy physiological state. Upon 
antigen-induced inflammation, mast cell progenitors are recruited to the respiratory 
endothelium. When mature mast cells are activated, more mast cell progenitors are 
recruited to the site of inflammation [40]. In addition to their primary  function in 
IgE-mediated allergic or anaphylactic responses, mast cells can mediate several 
modulatory effects. Mast cells produce cytokines than can drive CD4+ T cells 
and Treg cells to become IL-17 producing cells [41, 42]. Furthermore, mast cells 
can modulate dendritic cell maturation and function to promote TH1 and TH17 
responses [43]. Mast cells can recognize PAMPs via TLRs [39]. The expression 
of MHC class II and co-stimulatory molecules can be induced on human mast 
cells and these mast cells can act as antigen-presenting cells [44, 45]. Mast cell 
proteases can have anti-inflammatory activities, mainly through the degradation 
of pro-inflammatory cytokines and chemokines.
Dendritic cells: the link between innate and adaptive immunity
During pathogen invasion, DCs can recognize PAMPs through PRRs such as 
TLRs and become activated. Upon activation, DCs enhance their expression of 
class I and II MHC and co-stimulatory molecules. DCs become mature DCs and 
can then migrate to the draining lymph nodes. Dendritic cells are the only cells 
capable of stimulating naive CD4+ or CD8+ T lymphocytes through presentation 
of class I or II MHC-restricted antigen (peptide) to naive CD8+ or CD4+ T cells 
respectively. DCs play a crucial role in initiating tolerance, and polarized TH1, TH2 
and TH17 differentiation [46].
Trained innate immunity
Recently, the historical view that immunological memory is only a feature of 
the adaptive immunity has been challenged. Monocytes and macrophages that 
are exposed to microbial components (e.g., beta-glucan) or vaccination (e.g., 
with bacilli Calmette-Guerin, BCG) undergo epigenetic modifications that lead 
to increased cytokine production upon re-stimulation. NK cells showed features 
of trained immunity after BCG vaccination and can produce increased levels 
6of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) [47]. Excessive trained 
immunity was proposed in different disease, e.g. inflammatory and autoimmune 
disorders, allergies, cardiovascular diseases, specific infection and cancer [48]. 
Compared with blood monocytes from healthy individuals, blood monocytes from 
sarcoidosis patients express more TLR2 and TLR4 at baseline, and under certain 
conditions produce more inflammatory cytokines (TNF-α, IL-1β) [49]. Moreover, 
RNA-sequencing of blood monocytes of sarcoidosis patients revealed upregulation 
of genes involved in phagocytosis and lysosomal pathway. These results indicate 
that trained immunity could be a feature in sarcoidosis [50].
Human leucocyte antigen (HLA) 
In human, the major histocompatibility complex (MHC) region is located on the 
short arm of chromosome 6. In humans, this region is called human leukocyte 
antigen (HLA). Genes in this complex are subdivided into the extended class I, 
classical class I, classical class III, classical class II and extended class II regions 
[51]. Humans have three main MHC class I genes, i.e. HLA-A, HLA-B, and 
HLA-C. There are six main MHC class II genes in humans: HLA-DPA1, HLA-
DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1. The MHC class 
III region encodes various molecules important in the inflammatory response, e.g. 
complement components C2, C4, and factor B, and tumor necrosis factor-alpha 
(TNF-α). The function of the HLA class I and II molecules is to bind peptides 
and present them to the T-cell receptor (TCR) on T cells. HLA genes are closely 
linked, and the entire MHC is inherited as an HLA haplotype. The HLA region is 
associated with diseases (mainly autoimmune and infectious diseases) more than 
any other region of the genome [4, 52]. 
The class II region contains the classical class II alpha (a) and beta (b) chain genes, 
HLA-DP, -DQ, and -DR that are expressed on the surface of APCs to present pep-
tides to T-helper cells. In the nomenclature of genes in class II, HLA indicates the 
gene region; the first letter indicates the class (D); the second indicates the family 
(P, Q, or R) and the third letter designates the chain A (α) or B (β) followed by 
an asterisk that acts as a separator, followed by the number of the allele family 
and followed by the number of an allele variant. For example, HLA-DRB1*0301 
means the allele variant 01 of the allele family 03 that encodes the β chain of class 
II molecule of the DR family [52-54].
2.2 Adaptive Immunity
The adaptive immune response has two main characteristics: it can respond flexibly 
to new, previously unencountered antigens (antigenic specificity) and its potential 
to respond to previously encountered antigen (immunological memory) [2, 55-57].
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T cells are predominantly produced in the thymus and that is the cause for naming 
them T cells. T cells are subdivided into two lineages, CD4+ T cells (T helper, TH cells), 
and CD8+ T cells (cytotoxic T cells). 
TCRs are made up of pairs of chains: either α and β chains or γ and δ chains. 
However, γδ T cells are much less common than αβ T cells. T cell receptor α and 
β chains consist of variable (V) region and a constant (C) region. The TCRβ locus 
(chromosome 7) consists of variable (V), diversity (D), and joining (J) gene seg-
ments, and a constant (C) gene. The organization of TCRα locus (chromosome 14) 
is similar but with the absence of the D segment.
TCR is associated with CD3 complex that transmits activation signals into the cell 
when the T-cell receptor binds the peptide (antigen)-MHC complex [56].
Naïve CD4+ T cells
Human naive CD4+ T cells have an expected lifespan of 6–9 years. Naive CD4+T 
cells circulate between lymphoid organs (e.g. lymph nodes and spleen) and blood. 
In humans, naive CD4+ T cells express CD45RA and lack the expression of the 
memory-associated marker CD45RO [4]. Mature dendritic cells migrate to secondary 
lymphoid organs (such as regional lymph nodes) and interact with antigen-specific 
naïve CD4+ T cells. Three kinds of signals are required for activation and polariza-
tion of these naive CD4+ T cell. The first signal is the interaction of peptide-MHC 
II complex on dendritic cells with TCR on naive CD4+ T cells. The second signal 
is the interaction of co-stimulatory molecules such as CD80 or CD86 on dendritic 
cells with the CD28 receptor on naive CD4+ T cells. The third signal is the cytokines 
provided by the local environment that has a considerable impact on the differen-
tiation of naive CD4+ T cells into the effector subtypes, including TH1, TH2, TH17, 
and induced T regulatory cells (iTreg) [58]. 
TH1
IFN-γ and IL-12 are the central cytokines that promote the development of TH1 cells. 
IFN-γ induces the activation of the transcription factor STAT1, which induces the 
expression of the transcription factor T-bet. T-bet switches on the genes for IFN-γ 
and IL-12 receptor. IL-12 leads to the activation of the transcription factor STAT4, 
which leads to the expansion and differentiation of TH1 cells [59, 60].
TH2
IL-4 promotes the development of TH2 from naïve CD4+ T cells. TH2 cells produce 
IL-4, IL-5, and IL-13 and express the transcription factor GATA-3. Epigenetic 
regulation of GATA-3 is vital to sustaining the TH2 identity [59-61].
8TH17 T cells
TH17 cell subset was first identified in 2005 in the mouse as CD4+ T cells that pro-
duce IL-17 following in vitro activation. TH17 cells develop from antigen-activated 
naive CD4+ T cells in the presence of the cytokines IL-6, IL-21, and TGF-β. They 
are characterized by expression of the transcription factor RORγt and produce 
the cytokines IL-17A, IL17F and IL-22. The cytokines produced by TH17 acts on 
endothelial cells to induce the production of chemokines that recruit neutrophils to 
the site of infection. IL-23 is essential in amplifying the generation of TH17 cells 
and sustaining their survival. It is important to recall that cells of the innate and 
adaptive immune system other than TH17 cells, produce IL17 in vitro and in vivo. 
TH17 cells are usually identified (utilizing flow cytometry) by intracellular stain-
ing of IL-17, often following massive stimulation (e.g. with PMA/ionomycin). At 
this stage, these cells show important plasticity and can differentiate into effector 
or regulatory T cell subset. In tissue, where the local secretion of IL-17 occurs, 
the cells have a different morphology and appear to produce a single cytokine at 
a time. Both lymphocyte activation and cell contact with mesenchymal cells are 
critical for a high level of IL-17-production. Therefore, it is important to distinguish 
between intracellular staining and actual secretion of IL-17 [62].
Regulatory T cells (Treg cells) 
Tregs are T cells which have a role in suppressing other cells in the immune system. 
Tregs produced in the thymus are termed natural Treg cells (nTreg). Treg induced 
by differentiation of naive T cells outside the thymus, i.e., the periphery, or in cell 
culture are called ‘induced’ or ‘adaptive’ Treg cells (iTreg). Tregs are CD4+, CD25+ 
(the alpha chain of the IL-2 receptor), express the transcription factor FOXP3 and 
also express low levels of CD127 (the alpha chain of the IL-7 receptor). However, 
activated CD4+ T cells show expression of CD25, and ‘effector’ CD4+ T cells 
express FOXP3 upon activation. Accordingly, expression of CD25 and FOXP3 
cannot be used with confidence to quantify Treg cells. Hence, an in vitro assay that 
measures the ability of Treg cells to suppress CD4+ T cell proliferation might be 
used to test for Treg function. Tregs control inflammation and immune responses 
by diverse mechanisms of suppression: (1) secretion of the immunosuppressive 
cytokines IL-10, TG-β, and IL-35; (2) IL-2 consumption; (3) cytolysis of effector 
cell by producing granzyme and perforin; and (4) direct contact with dendritic 
cells through inhibitory co-receptors such as CTLA-4 [62, 63].
TH17/Treg balance
TGF-β can induce expression of FoxP3 and RORγt in TCR-stimulated naïve CD4 
+ T cells. In inflammatory conditions, FoxP3 expression is reduced, and RORγt 
expression is up-regulated that promotes TH17 differentiation. In the absence 
9of inflammation, TGF-β promotes Treg differentiation; this is due to a FoxP3-
mediated inhibition of RORγt. The developmental pathways of TH17 and Treg 
cells are reciprocally regulated and can affect the outcome of immune responses, 
especially in autoimmune and inflammatory diseases. [62, 64].
CD8+ T cells
CD8+ T cells are crucial for immune defense against intracellular pathogens, 
including viruses and bacteria, and for tumor surveillance. CD8+ T cells recog-
nize peptides presented by MHC Class I molecules, found on all nucleated cells. 
Activated CD8+ T cells secrete cytokines such as TNF-α and IFN-γ, which have 
anti-tumor, anti-viral and anti-microbial effects. CD8+ T cells kill their targets by 
inducing them to undergo apoptosis.
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3 PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTORS (PPARS)
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors that have a crucial role in various cellular processes,  including 
regulation of immune responses and inflammation [65]. PPARs are members of 
the nuclear receptor (NR) superfamily. There are three subtypes of PPARs, i.e. 
PPARα, PPARβ/δ, and PPARγ. The PPARs are expressed in different cells,  including 
macrophages and T lymphocytes [66, 67]. PPARs can be activated by natural 
(e.g. fatty acids, prostaglandins, leukotriene) and several synthetic ligands (e.g. 
fibrates and glitazones). After a ligand binding, PPAR translocates to the nucleus 
to heterodimerize with the retinoid X receptors (RXRs) thereby activating the 
expression of different genes (transactivation by direct binding to specific DNA 
response elements). Also, PPARs can downregulate the expression of pro-inflam-
matory genes by interfering with other transcription factors, e.g. NF-kB, STAT-1, 
and AP-1, but without direct binding to the DNA [66]. Hence, activating PPARα, 
PPARβ/δ, and PPARγ by ligands can inhibit TH1 pro-inflammatory cytokine pro-
duction by activated T cells . PPARα, and PPARγ exhibit immunomodulatory and 
anti-inflammatory effects in various inflammatory diseases, including pulmonary 
diseases such as COPD and asthma [68-72].
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4 SARCOIDOSIS
Sarcoidosis is a granulomatous disease of unknown etiology that can affect any 
organ but mainly affect the lung in >90% of the cases. Sarcoidosis is a multi factorial 
disease where interaction between environmental and genetic factors contribute 
to the pathogenesis of the disease.
4.1 Historical overview
Sir Jonathan Hutchinson (English surgeon, ophthalmologist, dermatologist, and 
pathologist; 1828-1069) was the first to describe a (sarcoid) skin plaque in London 
1869. In 1889, Ernest Besnier (French dermatologist; 1831-1909) described skin 
lesions associated with sarcoidosis as “lupus pernio”. In 1899, Caeser Boeck 
(Norwegian dermatologist; 1845-1917) used the term “multiple benign sarkoid of 
the skin”. Boeck used the term “sarkoid” because the lesions resembled sarcoma. 
Boeck was the first to describe the granulomatous histology of sarcoidosis and the 
involvement of multiple organs (e.g. the lungs, lymph nodes, and spleen). In 1909, 
Christian Friedrick Heerfordt (Danish ophthalmologist: 1871-1953) described a 
syndrome characterized by skin lesion, enlargement of parotid and submaxillary 
salivary glands, uveitis, and paresis of the cranial nerves and termed it “febris uveo-
parotidea subchronica”. In 1914, Jörgen Nilsen Schauman (Swedish dermatologist; 
1879-1953) described the systemic nature of the disease as “lymphogranuloma 
benigna”. Finally, Sven Löfgren (Swedish physician; 1910-1978) described 1953 
a syndrome consisting of fever, bilateral hilar lymphadenopathy, polyarthritis, and 
erythema nodosum that is now known as Löfgren’s syndrome [73, 74].
4.2 Epidemiology of sarcoidosis
The incidence and prevalence of sarcoidosis vary widely. The highest prevalence 
is reported in northern Europeans and African Americans. The prevalence and inci-
dence of sarcoidosis in Sweden are 160 and 11,5 per 100 000 per year respectively 
[75]. In the USA, the prevalence is 141 and 50 per 100 000 in African Americans 
and white people, respectively [76]. The incidence in Japan is much lower, 1.01 
per 100 000 [76].
In Sweden, individuals with sarcoidosis had a higher mortality rate (11 per 1000 
person-years) as compared to matched individuals from the general population 
(6.7 per 1000 person-years) [77].
Pulmonary fibrosis is detected in 4.7–15% of patients at presentation, with a sub-
sequent higher mortality rate as compared with the general population. Mortality 
is related to respiratory causes in 75% of cases [78]. Less than 5% of patients die 
from sarcoidosis [79]. 
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4.3 Etiology
The etiology of sarcoidosis remains speculative. Several lines of evidence point 
towards that sarcoidosis is an exaggerated immune response to persistent antigens 
from inorganic and/or organic agents or bacterial antigens derived from  incompletely 
degraded bacteria such as Mycobacteria and Cutibacterium acnes (previously known 
as Propionibacterium acnes). Vimentin is an endogenous antigen that might be 
involved in the pathogenesis of sarcoidosis. The unknown antigen probably varies 
according to the geographic distribution and occupational exposure.
It is likely that no single antigen is responsible for sarcoidosis but rather that various 
antigens could cause the disease. These antigens could be exogenous or endogenous, 
and this might explain the diversity in disease localization within the body [80-82].
4.4 Candidate gene association studies and 
 Genome-wide association studies
A various number of non-HLA genes have also been associated with risk of disease 
or phenotype. Examples include the association with the following genes: TGF-β, 
IL-23 receptor, TLRs, CCR2, and CCR5 [81, 83].
Genome-wide association studies revealed several loci that are associated with 
increased risk of sarcoidosis: C10orf67, ANXA11, BTNL2, CCDC88B, and  others 
[84-90]. 
Rivera et al, performed fine mapping analysis -using Immunochip- and identified 
727 LS-associated variants in the extended MHC region and two loci in ADCY3 
(2p23.3) and between CSMD1 and MCPH1 (8p23.1 - 8p23.2) outside the MHC 
region. Sixty-eight variants in the MHC II region associated with non-LS and two 
loci outside MHC region were identified, i.e. PLAC9 and ANXA11 (10q22.3) [90].
4.5 Clinical manifestations
Sarcoidosis can affect any organ, but the pulmonary system is involved in nearly 
all patients with sarcoidosis [76, 91]. A well-defined subgroup of sarcoidosis 
patients is Löfgren’s syndrome (LS), discriminated by an acute onset usually 
fever, bilateral hilar lymphadenopathy and in some cases, parenchymal infiltrates, 
erythema nodosum and/or bilateral ankle arthritis or periarticular inflammation. 
In Scandinavia, about one-third of sarcoidosis patients are LS. Several genetic 
loci associated with sarcoidosis, but the HLA region is the most relevant. HLA-
DRB1*0301 is strongly associated with LS and good prognosis. 95% of LS patients 
who are HLADRB1*03positive had a resolving disease within two years, where 49% 
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of HLA-DRB1*03negative LS patients developed a non-resolving disease. Thus, at 
our institution, the HLA-DRB1*0301 is used as a marker to predict remission or 
progression in LS patients. In the BALF of HLA-DRB1*03positive patients, there is an 
accumulation of specific Vα2.3/Vβ22 T cell receptor-expressing CD4+ T cells. The 
accumulation of Vα2.3/Vβ22 CD4+ T cells and the expression of HLA-DRB1*03 
on APCs suggest that a specific peptide is presented by HLA-DRB1*03. A vimentin 
peptide could be one of the offending antigens in LS. Thus, autoimmunity may 
contribute to the pathogenesis of sarcoidosis in these patients [82, 92-94].
The clinical picture of non-LS is heterogeneous and expand from chronic progres-
sive organ dysfunction to asymptomatic patients with accidental chest radiographic 
finding. In Swedish patients with non-LS, HLA-DRB1*14, and DRB1*15 asso-
ciated with the disease and they were risk factors for a non-resolving disease. In 
contrast, HLA-DRB1*01 and DRB1*03 protected against the disease. In particular, 
HLA-DRB1*03 protected against a non-resolving disease.
HLA class I alleles might also influence the disease course, and certain HLA 
allele-combinations was strongly associated with persistent disease (A*03, B*07, 
DRB1*15) [81, 94].
4.6 Granuloma formation in sarcoidosis
Generally, granulomas are defined as organized aggregates of macrophages, with 
functional and morphological changes, and other immune cells. Granulomas 
develop in response to persistent infectious and non-infectious stimuli that macro-
phages cannot eradicate [95]. Sarcoid granuloma consists of a central core that is 
 surrounded by mainly CD4+ T cells. The core includes macrophages and multi-
nucleate giant cells, which are fused macrophages, surrounded by large macro-
phages called epithelioid cells [96].
The initial step in granuloma formation is the activation of macrophages through 
binding of PRRs (e.g., TLR2) to PAMPS, and/or DAMPs ligands [97, 98]. Blood 
monocytes of sarcoidosis patients showed higher expression of TLR2 and TLR4 
as compared to healthy subjects [49]. Moreover, augmented secretion of the pro-
inflammatory cytokines TNFα and IL-1β was observed in sarcoidosis patients after 
combined TLR2 and NOD2 stimulation [49]. BAL cells of sarcoidosis patients 
showed enhanced production of proinflammatory cytokines (TNF-α and IL-6) after 
stimulation of the TLR-2/1 heterodimer and decreased response after stimulation 
of the TLR-2/6 heterodimer [99]. BAL macrophages stimulated with SAA showed 
enhanced production of TNF-α, IL-18, and IL-10 in sarcoidosis patients as com-
pared with control subjects, comprising mostly patients with chronic obstructive 
pulmonary disease. The effect of SAA on BAL macrophages is mediated in part 
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through TLR2 [100, 101]. Binding of a ligand to TLR2 initiates the activation of 
NF-kappa B pathway that stimulates the production of HLA-DR, co-stimulatory 
molecules (CD80, and CD86) and pro-inflammatory cytokines such TNF-α, 
chemokines, and adhesion molecules. TNF-α plays an essential role in granuloma 
formation and maintenance [80, 81, 102].
The next phase in granuloma formation is the interaction of MHC II-peptide 
complex on APCs with TCR on CD4+ T cells that leads to a polarized CD4+ 
response and the production of T-helper (TH) cytokines such as interferon-gamma 
(IFN-γ) and tumor necrosis factor-α (TNF-α) [101, 103]. Furthermore, TH17 CD4+ 
T cells were found within granuloma of sarcoidosis patients with active or relaps-
ing disease. Recently, TH1/TH17 CD4+ T cells that can produce both IL-17 and 
IFN-γ and co-express the transcription factors T-bet and RORγT were found in 
BAL from LS and non-LS patients. These cells represent the majority of CD4+ 
T cells. In non-LS, TH17/TH1 cells are the primary producers for IFNγ [104-106]. 
Furthermore, impaired regulatory T-cell function and alterations in the expression 
of co-inhibitory receptors that control T-cell responses, such as PD-1, CTLA-4, 
and BTNL2  suggest impaired T-cell regulation in pulmonary sarcoidosis. Within 
the granulomas, fibrosis can be induced with the production of TH2 cytokines (IL-4 
and IL-13) and TGF-β [96, 107-112].
Recent data showed that activation of mechanistic target of rapamycin complex 
1 (mTORC1) in macrophages – mTORC1 senses and integrates inputs from its 
surrounding to regulate the metabolism and growth of many cell types, including 
macrophages – drives their proliferation and hypertrophy, resulting in granuloma 
formation. Patients with progressive sarcoidosis showed a marked increase in 
expression of genes in the mTORC1 pathway, suggesting that mTORC1 con-
tributes to disease progression in sarcoidosis [110, 113].
In summary, granuloma formation in sarcoidosis is probably due to several abnorm-
alities that engage antigen/antigens clearance, exaggerated effector T cell response, 
and an aberrant granuloma signaling pathway (mTORC1) in macrophages [104, 
110, 114].
4.7 Diagnostic approach
The diagnosis of sarcoidosis is based on three criteria: clinical and radiographical 
presentation, the absence of an alternative diagnosis, and histological finding of 
non-caseating granuloma [115]. Histological diagnosis is not always needed and 
can be omitted in the setting of a classic clinical presentation, such as Löfgren’s 
syndrome.
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Chest radiographs are abnormal in 90% of cases at presentation. Lymphadenopathy 
occur in more than two-thirds of patients. Pulmonary infiltrates are present in 
20-50% of patients. Pulmonary fibrosis occurs in 20-25% of patients [76, 115]. 
Pulmonary sarcoidosis is usually classified into five stages according to findings 
on a conventional chest radiograph (Table 1).
Table 1. Chest radiographic findings of pulmonary sarcoidosis and prognosis [107, 
116, 117].
Stage Finding Prognosis
0 No obvious findings Not applicable
I Hilar or mediastinal nodal 
enlargement only
Spontaneous resolution occurs in 60-90%
II Nodal enlargement and 
 parenchymal disease
Spontaneous resolution occurs in 40-70%
III Parenchymal disease only Spontaneous resolution occurs in 10-20%
IV Pulmonary fibrosis Permanent organ dysfunction
High-resolution CT (HRCT) scan is more sensitive than chest radiograph in 
recognizing abnormalities and is sometimes but not regularly used for disease 
monitoring [76]. Pulmonary function tests (PFTs) are routinely performed and can 
show a restrictive or obstructive pattern. Diffusion capacity for carbon monoxide 
(DLCO) can be decreased.
Flexible bronchoscopy with bronchoalveolar lavage (BAL) are cornerstone 
investigations. During flexible bronchoscopy, endobronchial and transbronchial 
lung biopsy, and endobronchial ultrasound-guided transbronchial needle aspira-
tion can also be performed. BAL is a safe and minimally invasive procedure. 
Bronchoalveolar lavage fluid (BALF) cells comprise several subtypes [118]. In 
sarcoidosis patients, increased total BALF cell counts, lymphocytosis (>15% lym-
phocytes) and increased CD4/CD8 ratio (>3.5) are important findings [118, 119].
4.8 Sex differenced in sarcoidosis
Sex-specific differences are known in the immune responses [120] and in dif-
ferent pulmonary diseases, such as asthma and idiopathic pulmonary fibrosis 
[121]. Therefore, we investigated the sex-specific differences in LS and non-LS 
sarcoidosis patients.
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Comparison of LS-female versus LS-male
Compared with the LS-female group (42%), the LS-male (58%) group had higher 
macrophages, lymphocytes, basophils, and mast cells; lower BALF neutrophils; 
lower proportion of chest radiograph stage I and higher percentage of chest radio-
graph stage II (data not shown).
Comparison of non-LS-female vs non-LS-male
Compared with female (38%), male (62%) exhibited reduced PFTs (VC%, FVC%, 
TLC%). Also, male sex exhibited higher percentages of chest radiograph stage II 
and IV and was more predisposed to develop a non-resolving disease (data not 
shown). Moreover, non-resolving event associated with more likelihood with the 
male sex (OR: 1,48; 95% CI: 1,029; 2,12). In conclusion, male sex associated 
with increased disease severity as compared with the female group. The higher 
prevalence of male sex in this cohort is similar to prior results [122].
4.9 Age and Sarcoidosis
Another important aspect is the influence of ageing on sarcoidosis. Our results 
showed that the probability of non-resolving disease increase with age. A recent 
study showed that elderly patients (≥65 years) with sarcoidosis had more severe 
disease and death related to sarcoidosis was more prevalent in this group as com-
pared to younger patients [123]. Therefore, age is a predictor of higher morbidity, 
i.e. non-resolving disease.
4.10 Biomarkers in sarcoidosis
Several attempts have been made to identify reliable biomarkers that could reflect 
the inflammatory activity in sarcoidosis. Most frequently, serological tests have 
been reported, e.g. the levels of serum amyloid A (SAA), beta2-microglobulin, 
soluble IL-2 receptor (sIL2R), and the activity of angiotensin-converting enzyme 
(ACE), lysozyme, or chitotriosidase. Their value in diagnosing the disease and 
assessing the activity has been investigated. However, they are not specific or sen-
sitive enough to per se create a solid ground for decisions on how to manage the 
disease [124]. BALF cell characteristics could be useful biomarkers, e.g. increased 
lymphocytes, neutrophils, eosinophils, and mast cells [125, 126]. Currently, no 
single serum marker can be used for diagnosis, severity staging, or therapeutic 
response. However, the combination of serum and BALF differential cell counts 
might be useful in the appropriate clinical setting.
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4.11 Treatment of pulmonary sarcoidosis
Generally, treatment is mainly based on expert opinion and best clinical practice. 
Many patients with pulmonary sarcoidosis are asymptomatic, and spontaneous 
resolution occurs in approximately 60% of patients [76]. Thus, treatment is not 
indicated for asymptomatic patients with only mildly abnormal lung function.
The chest physician should consider initiating treatment in the following circum-
stances: worsening of respiratory symptoms (e.g. dyspnea), severe pulmonary 
dysfunction or deterioration of lung function (>10% reduction in FVC, or >15% 
reduction in DLCO from baseline measurements), or radiographical progression 
[76]. First-line therapy is monotherapy with oral corticosteroids. Methotrexate is 
the first choice as second-line glucocorticoid-sparing medicine. Azathioprine is 
an alternative.
TNF-α is crucial for the formation and maintenance of granuloma. TNF-α release 
from alveolar macrophages is higher in patients who have a progressive or corti-
costeroid-resistance disease than in patients with stable disease. Thus, anti-TNF-α 
agents may be an alternative in the treatment of refractory sarcoidosis and may 
constitute third-line therapies after failure of glucocorticoids and/or methotrexate/
azathioprine treatments [76, 127, 128].
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5 AIMS
5.1 Paper I
The aim of the study was to investigate the extent of AM polarization into M1 or 
M2 phenotypes in LS and non-LS patients as compared to HC. Additionally, we 
studied the expression of the innate immune receptors TLR2 and TLR4 in AM in 
LS and non-LS patients as compared to HC.
5.2 Paper II
This study aimed to gain more knowledge about the expression of all three PPARs 
(α, β/δ and γ) in BALF AM and BALF and blood CD4+ and CD8+ T cells in LS 
and non-LS patients as compared with HC.
5.3 Paper III
The study aimed to investigate the association between sarcoidosis-associated 
genetic variants and quantitative levels of BALF macrophages, lymphocytes, and 
neutrophils in LS and non-LS, respectively.
5.4 Paper IV
The study aimed to utilize data from a BALF registry of pulmonary sarcoidosis 
patients (LS and non-LS) to identify BALF cells that could predict disease severity 
(defined as advanced chest radiographs, reduced pulmonary function, or necessity 
for treatment) and/or chronicity (non-resolving course after two years).
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6 COMMENTS ON SUBJECTS AND METHODS
6.1 Study subjects
All included sarcoidosis patients in these studies were referred to the Lung and 
Allergy clinics (at Karolinska University Hospital or Södersjukhuset, Stockholm, 
Sweden) for an investigational work-up of clinically suspected pulmonary 
 sarcoidosis. The diagnosis of sarcoidosis was established according to the rec-
ommendations of the World Association of Sarcoidosis and other Granulomatous 
Disorders (WASOG) and other expert opinions [129, 130]. The diagnosis of sar-
coidosis based on three criteria: clinical and radiographical presentation, histo-
logical finding of non-caseating granuloma, and the exclusion of an alternative 
diagnosis. Histopathological diagnosis was not always needed and was omitted 
in the setting of a typical clinical presentation, such as Löfgren’s syndrome [107]. 
BAL was performed at the time of the diagnosis, and none of the patients was on 
anti-inflammatory or immune-suppressive treatment at this stage. All patients had 
a clinical picture completely consistent with sarcoidosis, and they were subdivided 
into two groups according to their clinical phenotypes: Löfgren’s syndrome (LS) 
and non-LS. Patients were also classified as being HLA allele DRB1*0301 positive 
(DR3postive) or DRB1*0301 negative (DR3negative). The percentages of the predicted 
percentages of vital capacity (VC), forced vital capacity (FVC), forced expiratory 
volume in 1 second (FEV1), total lung capacity (TLC), and diffusing capacity of 
the lung for carbon monoxide (DLCO) were obtained from the sarcoidosis regis-
try. VC, FVC, FEV1, and TLC were measured in liters. DLCO was measured in 
mmol/min/kPa. The radiological staging based on chest radiographs according to 
Scadding stages (0, I, II, III, IV) [131]. Healthy individuals were non-smokers, 
and none of them had signs of infection or inflammation at time of BAL. Written 
informed consent was obtained from all subjects, and the Regional Ethical Review 
Board (Stockholm, Sweden) approved the studies.
6.2 Bronchoalveolar lavage (BAL) and preperation 
of cells
Bronchoalveolar lavage fluid (BALF) has a central role in the diagnostic workup 
and differential diagnosis of sarcoidosis. BALF cells comprise different cell sub-
types, including macrophages, lymphocytes, and few percentages of basophils, 
eosinophils, neutrophils and mast cells . In conjunction with appropriate clinical 
and radiographic findings that are compatible with sarcoidosis, an increased total 
BALF cell counts, an accumulation of CD4+ T cells, and consequently, an increased 
BALF CD4/CD8 ratio (> 3.5 %) strongly promote the diagnosis of sarcoidosis.
BAL was performed as previously described [132]. Briefly, after light sedation and 
topical local anesthesia, a flexible fiber-optic bronchoscope was passed  trans-nasally 
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(in few cases trans-orally), and BAL was performed in a subsegmental bronchus 
in the middle-lobe using low-pressure suction technique. The expression of cell 
surface antigens (CD3, CD4, CD8) and the CD4+ to CD8+ cell ratio was performed 
by flow cytometric analysis using monoclonal antibodies against CD3+, CD4+, 
CD8+ as previously described [133].
Figure 2. Bronchoscopy of the lung simplified.
ROC curve to determine the best cut-off value(s) of BALF CD4/CD8 
ratio for the sarcoidosis diagnosis
Previous studies showed various cut-off values for CD4/CD8 ratio (ranging from 2 
to 4) [134]. A previous study showed that healthy-smoker had lower CD4/CD8 
ratio as compared with healthy-non-smoker [135]. Additionally, DR3 genotype 
(positive vs negative) may affect the CD4/CD8 ratio [136]. Thus, we determined 
to find the best cut-off value for entire LS patients, LS-non-smoker, LS-smoker, 
LS-ex-smoker, entire non-LS population, non-LS-non-smoker, non-LS-smoker, 
non-LS-ex-smoker, LS-DR3positive, LS-DR3negative, non-LS-DR3positive, and non-LS-
DR3negative, respectively.
The most appropriate cut-off value for CD4/CD8 ratio in all groups was >3.0, 
and the (entire sarcoidosis patients) sensitivity, specificity, likelihood ratio (LR), 
and AUC was 75%, 74%, 2.8, and 0.81 respectively. Smokers had a lower CD4/
CD8 ratio (but not statistically significant) as compared with non-smoker and ex-
smoker. The CD4/CD8 ratio was comparable between HLA-DRB1 *03positive vs 
HLA-DRB1*03negative groups (slightly higher in the positive group as compared 
with the negative group but did not reach statistical significance) (Table 3).
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A meta-analysis of BALF CD4/CD8 ratio from pooled 1885 sarcoidosis patients 
showed that sensitivity, specificity, and AUC was 70%, 80%, 0.84, respectively. 
As compared with this meta-analysis, our result demonstrated slightly higher 
sensitivity and lower specificity. In our analysis, the control group was healthy 
non-smoker volunteers. In the meta-analysis, the control group(s) was healthy non-
smoker individuals and other non-sarcoidosis pulmonary patients. The diversity 
in the control group might explain the slight difference in sensitivity, specificity. 
Also, our results confirm previous statements, that BALF CD4/CD8 ratio should 
only be used as an adjunctive tool and should be integrated with other clinical and 
laboratory results [107, 129, 130].
6.3 Monitoring gene expression: Real-time polymerase 
chain reaction (RT-PCR)
RT-PCR comprises several steps: 1- RNA isolation from specific cells; 2- reverse 
transcription of mRNA to cDNA; 3- amplification of specific DNA targets using 
polymerase chain reaction (PCR); and 4- determination of the initial concentra-
tion of the selected transcript.
6.3.1 RNA extraction and complementary DNA (cDNA) synthesis
Paper I
Total RNA was extracted via the guanidium thiocyanate-phenol-chloroform tech-
nique [137]. Briefly, cultured total BAL cells or AMs were incubated with RNA 
Bee (Nordic Biosite, Stockholm, Sweden). Then chloroform was added to separate 
the lysate into an aqueous and organic phase. Then centrifugation removes DNA 
and proteins from the aqueous phase that includes RNA. The RNA was precipitated 
from the aqueous phase by adding isopropanol. The RNA pellet was washed in 
75% ice-cold ethanol, followed by air-drying. The pellet was after that dissolved 
in autoclaved ultra-clean water.
To synthesize cDNA, 1μg of total RNA was incubated in the presence of 20 mM 
random hexamers primers (Pharmacia Biotech, Uppsala, Sweden) and 200 units 
Superscript™II RNase H- Reverse transcriptase (Invitrogen, Lidingö, Sweden) 
for 10 min at room temperature and then 45 min at 40°C, followed by 5 min at 
95°C to inactivate the enzyme. The cDNA samples were stored at -20°C until use.
Paper II
Depending on the cells count (≤5×105 or ≥ 106) total RNA was isolated using the 
RNAqueous-micro kit or the RNAqueous kit (Ambion®) according to the manu-
facturer’s instructions. The quantity of total RNA was analyzed using NanoDrop 
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ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
To synthesize cDNA, the high capacity RNA-to-cDNA kit (Invitrogen™) was 
used according to the manufacturer’s instructions.
6.3.2 RT-PCR
The important characteristic of RT-PCR is that amplification of cDNA is detected 
in real-time as PCR is progressing by using a fluorescent reporter. The fluorescent 
reporter signal intensity is directly proportional to the number of amplified DNA 
molecules. For relative quantification of the expression of cytokine genes in BALF 
cells, the following 2-ΔΔCT method was used [138]. In the first step, the Ct of 
the target gene (e.g. TLR2) was normalized to the endogenous control (β-actin: 
paper I, Proteasome Subunit, Beta Type, 2 (PSMB2): paper II). In the following 
step, normalization to the mean value of the target gene expression (e.g. TLR2) 
in a healthy control group (calibrator sample) was performed. The samples were 
run in duplicates to assure the validity of the experimentation.
Paper I
Real-time PCR was used to quantify the relative gene expression of M1 associ-
ated markers (IL-12p35, IL-12p40, IL-23p19, CCR7, iNOS, CXCL10, CXCL11, 
CXCL16, CCL20, CD80, CD86), M2 associated markers (IL-10, CCR2, CCL18), 
innate immune receptors (TLR2, TLR4, TLR9), and IL-7A, using ABI Prism 7700 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA).
Paper II
Real-time PCR was used to quantify the relative gene expression of PPAR α, β/δ, 
γ in BALF cells.
6.4 Flow cytometry
The immunologist uses flow cytometry for multiple purposes, e.g. to immunopheno-
type cells, measure intracellular cytokines and transcription factors, asses viability, 
or sort cells. Flow cytometry enables the researcher to obtain specific information 
about individual cells in a mixture of various cell populations.
A monoclonal antibody that is attached to a fluorochrome (e.g. FITC anti CD4+) is 
used to detect (stain) a specific extra- or intracellular protein (antigen). In a flow 
cytometer, cells are required to flow past the laser light one cell at a time. A flow 
cytometer detects fluorescence and light scattered from every single cell. A detec-
tor in front of the light beam measures forward scatter, and multiple  sensors to the 
side of the light beam sense side scatter. The path of light scattered by the cell cor-
responds to cell size and granularity. The fluorescent light emitted from stained sells 
is detected by sensors that can recognize emitted photons with a specific wavelength.
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Paper II
Flow cytometry was used to detect intracellular PPAR α, β/δ, γ on a single cell 
level in blood and BALF cells. Cells were analyzed on BD FACSCanto II flow 
cytometer (BD Bioscience), and data were processed using the web-based appli-
cation Cytobank [139] (Cytobank, Inc). 
Flow cytometric sorting of BAL macrophages and CD4+ T cells
BAL cells were stained with PE Mouse Anti-human CD4, clone RPA-T4. The 
stained cells were sorted by FACSVantage (BD Biosciences). BAL cells were 
gated on lymphocytes and macrophages, and the stained CD4+ T cells and macro-
phages were effectively separated. The purity of the sorted population, which was 
determined by flow cytometry, was approximately 98%.
6.5 Statistical analysis
We performed the nonparametric Mann-Whitney test and Kruskal-Wallis test 
to compare continuous variables. In the case of the Kruskal-Wallis test, Dunn’s 
post-test was used to compare the difference between groups. Fisher’s test and chi-
square test were used to compare categorical variables. Wilcoxon matched-pairs 
signed-rank test was used to compare two matched samples. Spearman correlation 
coefficient was calculated for the correlation between variables. P-values of <0,05 
were regarded as significant. We used the software GraphPad Prism for Windows 
(GraphPad Software, San Diego, California USA) to perform the analysis.
The receiver operating characteristic (ROC) curve was used to determine a proper 
cut-off value of CD4/CD8 ratio. Furthermore, we determined the most appropriate 
cut off-value for CD4/CD8 ratio in the entire sarcoidosis patients, and in sarcoidosis 
subgroups: total LS patients, LS-non-smoker, LS-smoker, LS-ex-smoker, entire 
non-LS population, non-LS-non-smoker, non-LS-smoker, non-LS-ex-smoker, 
LS-HLA-DRB1*03positive, LS-HLA-DRB1*03negative, non-LS-HLA-DRB1*03positive, 
and non-LS-HLA-DRB1*03negative. The most appropriate cut-off value was selected 
as that which combined maximal sensitivity with the best specificity. We used 
the ROUT method to exclude outliers in continuous variables (Q = 0,1%). Then, 
we performed the Grubb’s test for outlier testing to validate that the p-value was 
>0,05. We used the software GraphPad Prism version 8.2.1 for Windows (GraphPad 
Software, San Diego, California USA), and Minitab version 19.1.1 (Minitab 19 
Statistical Software (2010). State College, PA: Minitab, Inc.) to perform the tests.
Binary logistic regression method was used to predict the impact of the independ-
ent variable(s) (e.g. mast cells ≤10, mast cells >10) on the dependent binary vari-
able (e.g. resolving vs chronic). Minitab version 19.1.1. to perform the analyses 
and GraphPad Prism version 8.2.1 for Windows (GraphPad Software, San Diego, 
California USA) were used to perform the analysis.
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7 RESULTS AND DISCUSSION
This section will introduce the main findings of each paper, followed by a brief 
discussion.
7.1 Paper I
No evidence of altered alveolar macrophage polarization, but reduced expression 
of TLR2, in bronchoalveolar lavage cells in sarcoidosis
Main results and discussion
We found that AM of healthy individuals express both M1 and M2 markers in 
steady state. Mitis et al., found the same result [20].
In freshly isolated AMs, the relative gene expression of CCL18 (an M2 associ-
ated marker) was significantly higher in sarcoidosis patients compared to healthy 
individuals. Several studies found a positive correlation between BALF CCL18 
level and fibrotic lung diseases, e.g. idiopathic lung fibrosis, stage III and IV hyper-
sensitivity pneumonitis, and systemic sclerosis [140-142]. Also, plasma level of 
CCL18 was suggested to be a marker of disease activity [124, 143]. In our study, 
no correlations between CCL18 mRNA expression and chest radiograph stages or 
lung function parameters were found. But, most of our patients had chest radiograph 
stage I or II and only one patient had a chest radiograph of stage IV. Our finding 
is in concordance with the study by Cai et al., and again in this study, most of the 
patients had chest radiographic stage I and II, and only four patients had stage IV 
[144]. We did not observe any difference in CCL18 expression between LS and 
non-LS patients. Accordingly, CCL18 might serve as a T cell chemo attractant, in 
the early stages of the disease, and might exhibit a profibrotic role in more advanced 
disease. Interestingly, in mouse lungs CCL18 induced long-term pulmonary infil-
tration of T lymphocytes and consequently infiltration-dependent deposition of 
collagen through a TGF-β1-dependent mechanism [145].
Compared with healthy individuals, we found that AMs of sarcoidosis patients 
exhibited lower gene expression of TLR2. This finding was in disagreement with 
our previous published study of higher expression of TLR2 and TLR4 receptors 
on blood monocytes [49]. However, it should be emphasized that different cell 
types were analyzed (monocytes vs macrophages) and different methods were 
used (cell surface receptor expression vs mRNA expression). One reason for this 
discrepancy in TLR expression between lung and blood could be variations in 
exposure to different stimuli known to influence TLR expression. For instance, 
TLR ligands can up- or downregulate TLR mRNA expression depending on dose 
and time of the stimulus [49, 146, 147]. Moreover, the cell surface expression 
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of TLR2 was found to be increased by some cytokines and decreased by others 
[148], e.g. IFNγ and TNF downregulated TLR2 expression on human monocytes; 
although macrophages were not studied. Hence, the variety of inflammatory 
mediators presented in different compartments might contribute to the local TLR 
expression. Furthermore, the TLR2 down-regulation was mainly observed in LS 
patients, and this might indicate that AM encountered a specific microbial ligand 
that specifically binds to TLR2. Additionally, downregulation of TLR2 might have 
a role in the resolving of granuloma in LS patients.
In conclusion, the reduced gene expression of TLR2 (M1 associated marker) and 
the increased expression of CCL18 (M2 associated marker) in AM of sarcoidosis 
patients could indicate a shift toward M2-like macrophages. Recently, Shamaei 
et al., found enhanced CD163+ (M2 associated marker) staining of tissue samples 
(lung and lymph node) from sarcoidosis patients as compared with tuberculosis 
patients [149]. Furthermore, Locke at al., found that treatment of peripheral blood 
mononuclear cells (PBMCs) from sarcoidosis patients with purified protein deriva-
tive (PPD)-coated polystyrene beads resulted in the formation of granuloma-like 
multicellular aggregates and alternative (M2) macrophage polarization [150, 151].
7.2 Paper II
Reduced expression of peroxisome proliferator-activated receptor-alpha in BAL 
and blood T cells of non-Löfgren’s sarcoidosis patients
Main results and discussion
The expression of PPARs mRNA was investigated in total BALF cells in sarcoidosis 
patients and HC. In sarcoidosis patients, the mRNA expression of PPARα, PPARβ/δ 
and PPARγ did not differ significantly from HC. In non-LS patients, PPARβ/δ 
mRNA was increased as compared with LS patients and HC.
Compared with HC, LS and non-LS patients exhibited lower PPARα mRNA 
expression in FACS-sorted CD4+ T cells. Nevertheless, the mRNA expression 
of PPARα, PPARδ and PPARγ in FACS-sorted AM did not significantly differ in 
HC, LS and non-LS.
Furthermore, BALF CD4+ and CD8+ T cells of non-LS patients showed lower 
PPARα level as compared with LS patients. Additionally, PPARα and PPARγ 
 levels were reduced in blood CD4+ and CD8+ T cells of non-LS patients as com-
pared with LS. In AM, PPARs levels were comparable in LS, non-LS and HC.
Several studies showed that PPARα and PPARγ expression were downregulated 
in various inflammatory disorders. Furthermore, PPARγ expression was reduced 
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in PBMCs of multiple sclerosis patients and the colon of ulcerative colitis patients 
[152, 153]. Also, PPARγ expression was reduced in lung tissue and epithelial cells 
of COPD patients [154].
Idali et al., showed that the mRNA expressions of IFNγ and TNFα in BALF cells 
were reduced in DR3pos sarcoidosis patients (typically with Löfgren’s syndrome 
and resolving disease course) as compared with DR3neg patients [155]. Therefore, 
the reduced expression of PPARα in BALF and blood CD4+ and CD8+ T cells 
could contribute to higher expression of IFNγ and TNFα and in non-LS patients 
that are typically DR3neg and prone to develop a non-resolving disease course. 
Interestingly, studies showed that PPARα or PPARγ ligand activation decreases the 
expression of inflammatory cytokines, such as IFNγ and TNFα by TH1 cells [156, 
157]. Also, Fenofibrate (PPARα agonist) reduced the inflammatory response in 
allergen-induced airway inflammation in mice [158, 159]. Rosiglitazone (PPARγ 
agonist) treatment of patients with active ulcerative colitis or smokers with mild 
to moderate asthma resulted in clinical improvement [160, 161]. Thus, the reduced 
expression of PPARα or γ in CD4+ and CD8+ T cells in non-LS patients could 
act as a potential marker for disease activity and that treatment with PPARα and 
γ agonists might have a role in the treatment of non-LS patients with active or 
progressive disease.
In conclusion, we demonstrated for the first time, that PPARα and PPARγ expres-
sions are downregulated CD4+ and CD8+ T cells in non-LS patients as compared 
to LS patients.
7.3 Paper III
Influence of sarcoidosis risk genetic variants on the quantitative level of broncho-
alveolar lavage fluid (BALF) cell populations
Main results and discussion
Our results show that genetic variants associated with LS and located in the 
extended MHC region [90, 162] associated with the quantitative levels of BALF 
macrophages, lymphocytes, and neutrophils. Also, genetic variants associated 
with non-LS and located in the MHC class II region [90] were associated with the 
quantitative levels of BALF macrophages. These findings indicate a functional 
relationship between sarcoidosis genetic susceptibility and quantitative levels of 
BALF cells, which may modulate immune system functions. Interestingly,  several 
LS and non-LS genetic variants that associated with BALF cell types exhibit 
regulatory effect in lung, blood, T cells, B cells, macrophages, and neutrophils.
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Few limitations of this study can be addressed. Firstly, this study used only the 
SNPs that were associated with LS and non-LS, respectively. These SNPs represent 
only minority of the SNPs included in the Immunochip. Therefore, the association 
of other SNPs on other chromosomes that could also affect the quantitative level 
of BAL cell populations, was not evaluated. Furthermore, the genetic variants 
that associated with the quantitative levels of BALF cells are located within the 
MHC region are in strong linkage disequilibrium, and this should be considered 
when interpreting the results. Third, no association between genetic variants and 
BALF counts of basophils and eosinophils (in LS and non-LS) could be analyzed 
because a lot of the counts are nil.
In summary, our finding indicates that genetic variants associated with LS and 
non-LS have a pleiotropic effect on the quantitative level of BAL cell subpopula-
tions and this effect can contribute to the observed differences in BALF cell counts 
between LS and non-LS patients.
7.4 Paper IV
Bronchoalveolar lavage fluid cell subsets associate with the disease course in 
Löfgren’s and non-Löfgren’s sarcoidosis patients
Main results and discussion
This study illuminates the prognostic utility of BALF cells in newly diagnosed 
sarcoidosis patients. Compared with LS-resolving, LS-chronic patients exhibited 
higher percentages of BALF lymphocytes, neutrophils, and eosinophils. Also, in 
newly diagnosed LS patients, increased BALF lymphocytes (>24 x106/L) was more 
likely to predict a chronic disease course. In LS patients, DRB3pos is a marker for 
the best prognosis, i.e. resolving disease [163, 164] but HLA-genotyping might 
not be widely applied. Accordingly, increased BALF lymphocytes might be used 
as an alternative or complimentary predictor of chronicity when combined with 
other proper clinical parameters, e.g. older age at disease onset, and more advanced 
chest radiograph stages. Moreover, elevated BALF neutrophils and basophils 
associated with more severe disease, i.e. reduced TLC.
In sarcoidosis patients, DR3pos and DR15pos are markers for a resolving disease 
(best prognosis) and a chronic and progressive disease course (poor prognosis), 
respectively [165, 166]. BALF percentages of lymphocytes, eosinophils, baso-
phils, and mast cells count were higher in non-LS-DR15pos patients as compared 
with LS-DR3pos patients. Also, BALF mast cells were higher in non-LS-chronic 
patients as compared with non-LS-resolving patients. Additionally, higher BALF 
mast cells associated with more severe disease in newly diagnosed non-LS patients. 
Moreover, increased BALF basophils predicted the likelihood of treatment in 
newly diagnosed non-LS patients. 
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Our results confirm previously published findings in smaller studies that increased 
BALF mast cells, neutrophils, and eosinophils associate with a more severe disease 
course in non-LS patients, i.e. the majority of sarcoidosis patients [126, 167-169].
Neutrophils, eosinophils, basophils, and mast cells play a vital role in innate and 
adaptive immunity [26, 38, 39, 170-173]. For instance, mast cells, eosinophils, 
basophils, and neutrophils can induce T cell activation, proliferation, and cytokine 
secretion in an antigen-dependent manner [28, 38, 41, 172]. Mast cells can decrease 
the suppressive activity of Tregs [174] and can promote TH1 and TH17 responses 
[42, 43]. These data suggest that BALF mast cells, neutrophils, eosinophils, and 
basophils might contribute to the inflammatory response, granuloma formation 
and maintenance, disease severity and progression in pulmonary sarcoidosis.
In conclusion, this study suggests that increased BALF percentages of neutro-
phils, eosinophils, lymphocytes, basophils and notably mast cells might be used 
as prognostic markers in newly diagnosed sarcoidosis patients.
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8 CONCLUDING REMARKS
• In freshly isolated alveolar macrophages (AM) of sarcoidosis patients, we iden-
tified a reduced gene expression of TLR2 (M1 associated marker), especially 
in patients with LS. In addition, there was an increased expression of the M2 
associated marker CCL18 in sarcoidosis versus controls (HC), indicating a 
shift toward M2-like macrophages.
• We found no significant difference in PPARs expression in AMs of sarcoidosis 
patients and HC.
• In non-LS patients, PPARα expression was downregulated in BALF and blood 
CD4+ and CD8+ T cells, and the expression of PPARγ was reduced in blood 
CD4+ and CD8+ T cells. 
• PPARα and CCL18 could potentially be used as biomarkers of active or 
advanced disease.
• Genetic variants associated with LS are significantly associated with the 
quantitative levels of BALF macrophages, lymphocytes, and neutrophils.
• Genetic variants associated with non-LS are associated with the number of AM.
• Several sarcoidosis risk gene variants -that are also expressed in lung and 
immune cell types- control the expression of nearby genes, thus highlighting 
a pleiotropic phenomenon between disease genetic susceptibility and the local 
immune response (the lungs).
• BALF cell subsets have prognostic implications in sarcoidosis.
• As compared to LS-DR3pos patients, non-LS DR15pos patients exhibited higher 
BALF lymphocytes, eosinophils, basophils, and mast cells.
• Overall, signs of an exaggerated immune response, reflected by lung accumula-
tions of different cell-types, usually associated with a more severe and chronic 
disease.
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9 FUTURE PERSPECTIVES
In the era of precision and individualized medicine, the clinician needs to consider 
multiple clinical parameters, biomarkers, the genetic variability of the disease, and 
different disease endotypes or deep phenotypes to predict the prognosis and or 
disease activity and to choose the appropriate treatment. One example is CCL18, 
which potentially could be used as a biomarker to predict patients at higher risk 
of progressing to lung fibrosis, another is PPARα, which could have prognostic 
and therapeutic implications, though further studies are required.
Non-LS patients constitute a heterogeneous group and geno- and endotyping (signi-
fying subtypes of the disease) this group more in detail is of clinical relevance. We 
have shown that subtyping this group of mixed patients according to BALF cell 
characteristics (lymphocytic, neutrophilic, basophilic, eosinophils, and increased 
mast cells count) could help in predicting the disease course. Cytospin with  specific 
cell staining is the procedure currently used, however time-consuming, to determine 
the BALF cell counts. Flow cytometry could alternatively be used to determine the 
accurate counts of different BALF cells quickly and correctly, and to evaluate the 
expression of various activation- and cell line specific-markers. We have shown 
that some of our previously identified sarcoidosis associated genetic variants can 
influence the BALF cell number. In the future, more detailed genome-wide associa-
tion studies applied on more significant numbers of clinically well-characterized 
patients may reveal new genetic variants that could influence differential BALF 
cells and the inflammatory process in sarcoidosis.
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